CDA | Evidence Driven
CDA | Evidence Driven

Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness

Details

Files
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0672-000

Question

  1. What is the comparative clinical effectiveness of ACE inhibitors for reducing blood pressure, kidney protection, and other outcomes?
  2. What is the comparative cost-effectiveness of ACE inhibitors for reducing blood pressure, kidney protection, and other outcomes?
  3. What is the comparative clinical effectiveness of ACE inhibitors for reducing blood pressure, kidney protection, and other outcomes?

Key Message

Limited evidence exists in support of different effects of individual ACE inhibitors; imidapril might be better than ramipril in reducing urinary albumin excretion in diabetic patients with HTN, and zofenopril could be better than ramipril in reducing the number of hospitalization in post-acute MI patients, with a comparatively favorable cost-effectiveness profile. Zofenopril, however, is not available in Canada. Evidence for other outcomes suffers from several methodological limitations.Limited evidence of moderate quality indicates that adding a diuretic to an ACE inhibitor can improve diastolic blood pressure control, but may also reduce the beneficial effects of ACE inhibitors on glycemic control and metabolic profile.

Files

Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness Rapid Response June 12, 2015 View PDF
Last Updated : June 12, 2015